{"id":93009,"date":"2023-03-01T19:00:00","date_gmt":"2023-03-01T13:30:00","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=93009"},"modified":"2023-03-01T16:52:49","modified_gmt":"2023-03-01T11:22:49","slug":"block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/","title":{"rendered":"Block Deal: FIIs buy a stake in this pharma stock, Analyst sees an upside of 17%\u00a0"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-3137705836\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>With a market capitalization of \u20b9 27,352 crores, Biocon is a mid-cap company in the pharmaceutical sector. It is India\u2019s largest fully-integrated, innovation-led biopharmaceutical company that is driven by a passion to develop research-driven, cutting-edge therapies.&nbsp;<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-296345120\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><p>According to the bulk deal data available on the National Stock Exchange (NSE), Integrated Core Strategies (Asia) Pte. has bought 80,61,599 shares of Biocon Ltd. These shares were bought at an average price of \u20b9 229.26 per share, taking the aggregate value of the transaction to \u20b9 184.82 crores.&nbsp;<\/p><p><a href=\"https:\/\/portal.tradebrains.in\/stock\/BIOCON\/consolidated\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>Biocon\u2019s<\/strong><\/a> shares are in a downtrend and have lost 33.94% in the past year. Analysts attribute this fall to the company\u2019s weak results, a recall of its drug bottles, removal from Nifty Next 50 and its recent move to reduce a stake in its research arm Syngene.\u00a0<\/p><p>The company reported a 35% increase in its consolidated net profit for the quarter that ended on December 31, 2022, at \u20b9 2,941.10 crores, against \u20b9 2174.2 crores reported in the corresponding quarter last year. However, it reported a loss of \u20b9 207 crores in the October to December quarter of 2022 against a profit of \u20b9 2196 crores in the corresponding quarter last year.&nbsp;<\/p><div class=\"trade-content_5\" id=\"trade-2835731766\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><p>Last month, Biocon sold a 9.96% stake in its unit and contract research firm Syngene International to fund the acquisition of Viatris Inc&#8217;s (VTRS.O) biosimilars business that it announced last year, according to reports.&nbsp;<\/p><p>In another development, Biocon recalled 3,665 bottles of an antifungal drug in the US for failed degradation specifications, according to USFDA US Food and Drug Administration&nbsp;<\/p><p>The Bangalore-based company has a return on equity of 8.08% and an ideal debt-to-equity ratio of 0.61. The company\u2019s shares were trading at a price-to-earnings ratio of 70.80, which is significantly higher than the industry P\/E of 35.25, indicating that the stock might be overvalued as compared to its peers.&nbsp;<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by Simran Bafna&nbsp;<\/strong><\/p><\/blockquote><h4 class=\"wp-block-heading\" id=\"h-disclaimer\"><strong>Disclaimer<\/strong><\/h4><div class=\"wp-block-image\"><figure class=\"aligncenter size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer.png\" alt=\"\" class=\"wp-image-26306\" width=\"256\" height=\"256\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.<\/strong><\/p><div class=\"trade-after-content\" id=\"trade-1686929270\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>With a market capitalization of \u20b9 27,352 crores, Biocon is a mid-cap company in the pharmaceutical sector. It is India\u2019s largest fully-integrated, innovation-led biopharmaceutical company that is driven by a passion to develop research-driven, cutting-edge therapies.&nbsp; According to the bulk deal data available on the National Stock Exchange (NSE), Integrated Core Strategies (Asia) Pte. has [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":82826,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[2460,6893,6897,6895,5874,2461,6892,6894,6896,5239,6902,6901,6898,6899,6616,3047,5890,3046,6617,6900,948,936,3153,3157,2597],"class_list":["post-93009","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news","tag-biocon","tag-biocon-block-deal","tag-biocon-deals","tag-biocon-latest-news","tag-biocon-limited","tag-biocon-q3-results","tag-biocon-results-2023","tag-biocon-share-price","tag-biocon-targets","tag-block-deal","tag-block-deal-2023","tag-block-deals","tag-fii-stake-in-biocon","tag-fii-stake-in-biocon-2023","tag-pharma-stock","tag-pharma-stocks","tag-pharma-stocks-latest-news","tag-pharma-stocks-to-buy","tag-pharma-stocks-to-buy-now","tag-sharekhan-targets","tag-stock-market","tag-stock-market-news","tag-stock-to-buy","tag-stock-to-watch","tag-stocks-to-watch"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Block Deal: FIIs buy a stake in this pharma stock, Analyst sees an upside of 17%\u00a0 - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"The company reported a 35% increase in its consolidated net profit for the quarter that ended on December 31, 2022, at \u20b9 2,941.10 crores, against \u20b9 2174.2 crores reported in the corresponding quarter last year. However, it reported a loss of \u20b9 207 crores in the October to December quarter of 2022 against a profit of \u20b9 2196 crores in the corresponding quarter last year.\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Block Deal: FIIs buy a stake in this pharma stock, Analyst sees an upside of 17%\u00a0\" \/>\n<meta property=\"og:description\" content=\"The company reported a 35% increase in its consolidated net profit for the quarter that ended on December 31, 2022, at \u20b9 2,941.10 crores, against \u20b9 2174.2 crores reported in the corresponding quarter last year. However, it reported a loss of \u20b9 207 crores in the October to December quarter of 2022 against a profit of \u20b9 2196 crores in the corresponding quarter last year.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-01T13:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/pharma-cover-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/pharma-cover-image.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/\",\"url\":\"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/\",\"name\":\"Block Deal: FIIs buy a stake in this pharma stock, Analyst sees an upside of 17%\u00a0 - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/pharma-cover-image.jpg\",\"datePublished\":\"2023-03-01T13:30:00+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"The company reported a 35% increase in its consolidated net profit for the quarter that ended on December 31, 2022, at \u20b9 2,941.10 crores, against \u20b9 2174.2 crores reported in the corresponding quarter last year. However, it reported a loss of \u20b9 207 crores in the October to December quarter of 2022 against a profit of \u20b9 2196 crores in the corresponding quarter last year.\u00a0\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/pharma-cover-image.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/pharma-cover-image.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Block Deal: FIIs buy a stake in this pharma stock, Analyst sees an upside of 17%\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Block Deal: FIIs buy a stake in this pharma stock, Analyst sees an upside of 17%\u00a0 - Trade Brains Features","description":"The company reported a 35% increase in its consolidated net profit for the quarter that ended on December 31, 2022, at \u20b9 2,941.10 crores, against \u20b9 2174.2 crores reported in the corresponding quarter last year. However, it reported a loss of \u20b9 207 crores in the October to December quarter of 2022 against a profit of \u20b9 2196 crores in the corresponding quarter last year.\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/","og_locale":"en_US","og_type":"article","og_title":"Block Deal: FIIs buy a stake in this pharma stock, Analyst sees an upside of 17%\u00a0","og_description":"The company reported a 35% increase in its consolidated net profit for the quarter that ended on December 31, 2022, at \u20b9 2,941.10 crores, against \u20b9 2174.2 crores reported in the corresponding quarter last year. However, it reported a loss of \u20b9 207 crores in the October to December quarter of 2022 against a profit of \u20b9 2196 crores in the corresponding quarter last year.\u00a0","og_url":"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2023-03-01T13:30:00+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/pharma-cover-image.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_image":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/pharma-cover-image.jpg","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/","url":"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/","name":"Block Deal: FIIs buy a stake in this pharma stock, Analyst sees an upside of 17%\u00a0 - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/pharma-cover-image.jpg","datePublished":"2023-03-01T13:30:00+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"The company reported a 35% increase in its consolidated net profit for the quarter that ended on December 31, 2022, at \u20b9 2,941.10 crores, against \u20b9 2174.2 crores reported in the corresponding quarter last year. However, it reported a loss of \u20b9 207 crores in the October to December quarter of 2022 against a profit of \u20b9 2196 crores in the corresponding quarter last year.\u00a0","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/pharma-cover-image.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/pharma-cover-image.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/block-deal-fiis-buy-a-stake-in-this-pharma-stock-analyst-sees-an-upside-of-17\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Block Deal: FIIs buy a stake in this pharma stock, Analyst sees an upside of 17%\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/93009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=93009"}],"version-history":[{"count":2,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/93009\/revisions"}],"predecessor-version":[{"id":93016,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/93009\/revisions\/93016"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/82826"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=93009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=93009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=93009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}